Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk



      Using data from a case-control study of endometrial cancer, we investigated the relationship between the progestin and estrogen potency in combination oral contraceptives (OCs) and the risk of developing endometrial cancer.


      Subjects included 434 endometrial cancer cases and 2557 controls identified from the Cancer and Steroid Hormone (CASH) study. OCs were classified into four categories according to the individual potencies of each hormonal constituent (high versus low estrogen or progestin potency). Logistic regression was used to evaluate associations between endometrial cancer risk and combination OC formulations.


      With non-users as the referent group, use of OCs with either high potency progestin [odds ratio for endometrial cancer (OR)=0.21, 95% confidence interval (CI)=0.10 to 0.43] or with low potency progestin (OR=0.39, 95% CI=0.25 to 0.60) were both associated with a decreased risk of endometrial cancer. Overall high progestin potency OCs did not confer significantly more protection than low progestin potency OCs (OR=0.52, 95% CI=0.24 to 1.14). However, among women with a body mass index of 22.1 kg/m2 or higher, those who used high progestin potency oral contraceptives had a lower risk of endometrial cancer than those who used low progestin potency oral contraceptives (OR=0.31, 95% CI=0.11 to 0.92) while those with a BMI below 22.1 kg/m2 did not (OR=1.36, 95% CI=0.39 to 4.70).


      The potency of the progestin in most OCs appears adequate to provide a protective effect against endometrial cancer. Higher progestin-potency OCs may be more protective than lower progestin potency OCs among women with a larger body habitus.


      To read this article in full you will need to make a payment


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Parazzini F.
        • Vecchia C.L.
        • Bocciolone L.
        • Franceshi S.
        The epidemiology of endometrial cancer.
        Gynecol Oncol. 1991; 41: 1-16
        • Horn-Ross P.L.
        • John E.M.
        • Canhola A.J.
        • Sterwart S.L.
        • Lee M.M.
        Phytoestrogen intake and endometrial cancer risk.
        JNCI. 2003; 95: 1158-1164
        • McPherson C.P.
        • Sellers T.A.
        • Potter J.D.
        • Bostick R.M.
        • Folsom A.R.
        Reproductive factors and risk of endometrial cancer. The Iowa women's health study.
        Am J Epidemiol. 1996; 143: 1195-1202
        • The Writing Group for the PEPI trial.
        Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial.
        JAMA. 1996; 275: 370-375
        • Stanford J.L.
        • Brinton L.A.
        • Berman M.L.
        • Mortel R.
        • Twiggs L.B.
        • Barrett R.J.
        • et al.
        Oral contraceptives and endometrial cancer: do other risk factors modify the association?.
        Int J Cancer. 1993; 54: 243-248
        • Randall T.C.
        • Kurman R.J.
        Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40.
        Obstet Gynecol. 1997 (Sep); 90: 434-440
        • Rosenblatt K.A.
        • Thomas D.B.
        Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma: the WHO collaborative study of neoplasia and steroid contraceptives.
        Int J Cancer. 1991; 49: 870-874
        • Schildkraut J.M.
        • Calingaert B.
        • Marchbanks P.A.
        • Moorman P.G.
        • Rodriguez G.C.
        Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer sik.
        J Natl Cancer Inst. 2002; 94: 32-38
        • Rodriguez G.C.
        • Walmer D.K.
        • Cline M.
        • Krigman H.
        • Lessey B.A.
        • Whitaker R.S.
        • et al.
        Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?.
        J Soc Gynecol Invest. 1998; 5: 271-276
        • Rodriguez G.C.
        • Haisley C.
        • Hurteau J.
        • Moser T.L.
        • Whitaker R.
        • Bast Jr., R.C.
        • et al.
        Regulation of invasion of epithelial ovarian cancer by TGF-Beta.
        Gynecol Oncol. 2001; 80: 245-253
        • Anonymous
        Combination oral contraceptive use and the risk of endometrial cancer. The cancer and steroid hormone study of the centers for disease control and the national institute of child health and human development.
        JAMA. 1987; 257: 796-800
        • Piper J.
        • Kennedy D.
        Oral contraceptive in the United States: trends in content and potency.
        Int J Epidemiol. 1987; 16: 215-221
        • Anonymous
        Endometrial cancer and combined oral contraceptives. The who collaborative study of neoplasia and steroid contraceptives.
        Int J Epidemiol. 1988; 17: 263-269
        • Voigt L.F.
        • Deng Q.
        • Weiss N.S.
        Recency, duration and progestin content of oral contraceptives in relation to the incidence of endometrial cancer.
        Cancer Causes Control. 1994; 5: 227-233
        • Reis F.M.
        • Ribeiro M.F.
        • Maia A.L.
        • Spritzer P.M.
        Regulation of human endometrial transforming growth factor beta1 and beta3 isoforms through menstrual cycle and medroxyprogesterone acetate treatment.
        Histol Histopathol. 2002; 17: 739-745
        • Bianchini F.
        • Kaaks R.
        • Vainio H.
        Overweight, obesity and cancer risk.
        Lancet Oncol. 2002; 3: 565-574
        • Goodman M.T.
        • Hankin J.H.
        • Wilkens L.R.
        • Lyu L.C.
        • McDuffie K.
        • Liu L.Q.
        • et al.
        Diet, body size, physical activity, and the risk of endometrial cancer.
        Cancer Res. 1997; 57: 5077-5085
        • Bergsrtom A.
        • Pisani P.
        • Tenet V.
        • Wolk A.
        • Adami H.-O.
        Overweight as an avoidable cause of cancer in Europe.
        Int J Cancer. 2001; 91: 421-430
      1. American Obesity Association: http//

      2. National Health and Nutrition Examination Survey (NHANES) by the Centers for Disease Control.

        • Calle E.E.
        • Rodriguez C.
        • Walker-Thurmond K.
        • Thun M.J.
        Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.
        NEJM. 2003; 348: 1625-1638